
Japanese health authorities said on Wednesday that they will soon make a decision on a possible penalty against the local unit of Swiss pharmaceutical giant Novartis for failing to report drug side effects.
That followed media reports which said regulators would slap a 15-day suspension order on the firm, meaning the company could not sell most of its drugs during the two-week period -- a first for a pharmaceutical firm operating in Japan.
Tokyo-based Novartis Pharma K.K. in December admitted it failed to report more than 3,000 cases of patient health problems that may have been caused by adverse effects from about two dozen company drugs.
The Swiss firm's Japanese unit declined to comment Wednesday, while the health ministry said that a decision was imminent.
"We haven't decided anything yet, but it should be announced soon," a spokesman told AFP.
The possible penalty marks the latest headache for the drugmaker in Japan.
In July it was handed a business improvement order for failing to properly report side effects of two leukaemia drugs.
Also in July prosecutors laid charges against the unit over claims that falsified data were used to exaggerate the benefits of a popular blood-pressure drug.
They also indicted a former employee, Nobuo Shirahashi, alleging he manipulated the data in clinical studies that were later used in marketing the drug Valsartan.
GMT 09:47 2018 Tuesday ,23 January
SAP unveils big push into French tech start-upsGMT 05:07 2018 Tuesday ,23 January
Noble Group shares surge 37 percent on buyout talksGMT 19:07 2018 Monday ,22 January
BAKS spent Dh225m on charity projects in 2017GMT 22:52 2018 Sunday ,21 January
French firm "recalls baby milk product"GMT 22:27 2018 Sunday ,21 January
US company plans funds that double bitcoin price movesGMT 21:23 2018 Sunday ,21 January
Pence starts Mideast tour in Egypt amid Arab angerGMT 08:54 2018 Saturday ,20 January
Million-euro bill for firm behind Paris bike-share chaosGMT 10:47 2018 Friday ,19 January
German chemical giant BASF sees 'significant' profit leap

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor